Director John W. Kozarich of Ligand Pharmaceuticals Inc filed a Form 144 notice on November 12, 2026, proposing the sale of 500 shares of Ligand common stock through UBS Financial Services, Inc., with an approximate sale date of November 12, 2026.

Key Highlights

  • Seller and role: John W. Kozarich, identified in the filing as a Director of Ligand Pharmaceuticals Inc.
  • Shares proposed for sale: 500 shares of common stock, with an aggregate market value listed as $162,500.00.
  • Shares outstanding: 20,002,986 shares of common stock outstanding, according to the filing.
  • Acquisition history: The 500 shares were received in two stock awards from the issuer: 250 shares on February 28, 2022, and 250 shares on June 6, 2025.
  • Prior sale disclosed: The filing reports a sale of 500 shares on November 11, 2026, generating gross proceeds of $158,658.00.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of August 12, 2026, pursuant to Rule 10b5-1 of the Exchange Act.
  • Broker: UBS Financial Services, Inc., Eleven Madison Avenue, 4th Floor, New York, NY 10010.

Kozarich's Proposed November 2026 Share Sale at Ligand Pharmaceuticals

According to the Form 144 filing submitted November 12, 2026, Director John W. Kozarich proposed to sell 500 shares of common stock in Ligand Pharmaceuticals Inc (NASDAQ:LGND) through UBS Financial Services, Inc. The aggregate market value of those shares was listed as $162,500.00. Ligand Pharmaceuticals, headquartered at 3911 Sorrento Valley Blvd, Suite 110, San Diego, California 92121, is a biopharmaceutical company whose SEC file number is listed as 001-33093 in the filing.

The filing discloses that the 500 shares proposed for sale were acquired in two separate stock award transactions from the issuer: 250 shares awarded on February 28, 2022, and 250 shares awarded on June 6, 2025. No cash payment is indicated for either acquisition, as both are described as stock awards from the issuer. The filing also reports that within the three months prior to this notice, Kozarich sold 500 shares of common stock on November 11, 2026, for gross proceeds of $158,658.00, also conducted through UBS Financial Services, Inc.

The notice states a Rule 10b5-1 plan adoption date of August 12, 2026. Under this rule, a trading plan adopted at a time when the person is not aware of material nonpublic information can allow pre-scheduled securities transactions to proceed at a later date. The total shares of Ligand common stock outstanding at the time of filing were reported as 20,002,986. The filing was signed by UBS Financial Services Inc. as attorney-in-fact for John Kozarich.

What Was Disclosed

Ligand Pharmaceuticals Director John W. Kozarich filed a Form 144 on November 12, 2026, proposing the sale of 500 shares of common stock valued at $162,500.00, acquired via two stock awards from the issuer in 2022 and 2025, under a Rule 10b5-1 plan adopted August 12, 2026.